ArticleAmerican journal of translational research2022
A retrospective analysis of relapse-related factors for ovarian borderline tumors.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A new risk algorithm combining D-dimer and HE4 differentiates borderline tumor from patients with ovarian tumor.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSince patients with borderline ovarian tumors (BOTs) are relatively young with good survival rates, conservative surgery is prioritized as a therapeutic intervention. However, the high recurrence rate of this tumor remains an issue that demands further attention. In addition, it is unclear whether the increment of recurrent risk is attributed to conservative surgery or staging surgery. This study was designed to analyze the relapse-related factors of BOTs.
methodsThis retrospective cohort study was comprised of 74 patients with BOTs who underwent surgery at the Obstetrics and Gynecology Hospital of Fudan University from September 2014 to September 2017. The recurrence-free survival (RFS) rate was calculated using the Kaplan-Meier method, while the risk factors of RFS were evaluated using Cox-regression analysis.
resultsThe 3-year RFS was 2.7% with a median follow-up duration of 45 months (range: 28-62). Kaplan-Meier analysis indicated that low tumor node metastasis (TNM) stage (P = 0.005), lymphadenectomy (P = 0.052) and fertility-preservation surgery (P = 0.059) were the factors that may lower recurrence. Meanwhile, Cox-regression showed that only low TNM stage was significantly associated with a better RFS (P = 0.005).
conclusionsWith the removal of visible lesions by standard surgery, patients at TNM stage I had a better RFS. Fertility-preservation surgery did not increase the recurrence risk. For bilateral ovarian cyst however, it was unclear whether bilateral cystectomy can increase the recurrence risk. Therefore, further study is required.
Indexed as
Identifiers
36105008PMC9452353What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.